ResearcherSun Yat-sen UniversityActive in the last 2 years
Shengping Li
Matched on ORCID iD 0000-0001-6940-9179; OpenAlex author ID A5100732813. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 13
2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper
Papers 5
- Irreversible electroporation is superior to resection for locally advanced pancreatic cancer after neoadjuvant chemotherapy. Last author DOI 10.1016/j.hbpd.2026.05.003↗
- Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC. Co-author DOI 10.1016/j.tranon.2024.102206↗
- Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of pancreatic cancer: a mendelian randomization analysis. Co-author DOI 10.1186/s12885-025-13824-7↗
- Nomogram for predicting post-progression-free survival in patients with recurrent pancreatic ductal adenocarcinoma after radical surgery: a retrospective analy… Last author DOI 10.3389/fmed.2024.1486750↗
- Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia. Co-author DOI 10.1016/j.ejso.2019.12.006↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zehui Yao · 4 shared papers, 2024–2026 · strength 1.07
- Paper Irreversible electroporation is superior to resection for locally advanced pancreatic cancer after neoadjuvant chemothe… DOI 10.1016/j.hbpd.2026.05.003↗
- Paper Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of pancreatic cancer: a mendelian … DOI 10.1186/s12885-025-13824-7↗
- Paper Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential … DOI 10.1016/j.tranon.2024.102206↗
- Pu Xi · 4 shared papers, 2024–2026 · strength 1.07
- Paper Irreversible electroporation is superior to resection for locally advanced pancreatic cancer after neoadjuvant chemothe… DOI 10.1016/j.hbpd.2026.05.003↗
- Paper Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of pancreatic cancer: a mendelian … DOI 10.1186/s12885-025-13824-7↗
- Paper Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential … DOI 10.1016/j.tranon.2024.102206↗
- Dailei Qin · 3 shared papers, 2024–2025 · strength 0.77
- Paper Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of pancreatic cancer: a mendelian … DOI 10.1186/s12885-025-13824-7↗
- Paper Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential … DOI 10.1016/j.tranon.2024.102206↗
- Paper Nomogram for predicting post-progression-free survival in patients with recurrent pancreatic ductal adenocarcinoma afte… DOI 10.3389/fmed.2024.1486750↗
- Ran Wei · 2 shared papers, 2024–2025 · strength 0.49
- Paper Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential … DOI 10.1016/j.tranon.2024.102206↗
- Paper Nomogram for predicting post-progression-free survival in patients with recurrent pancreatic ductal adenocarcinoma afte… DOI 10.3389/fmed.2024.1486750↗
- Lingmin Jiang · 2 shared papers, 2024–2025 · strength 0.49
- Paper Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential … DOI 10.1016/j.tranon.2024.102206↗
- Paper Nomogram for predicting post-progression-free survival in patients with recurrent pancreatic ductal adenocarcinoma afte… DOI 10.3389/fmed.2024.1486750↗
- Chao-Bin He · 1 shared paper, 2026 · strength 0.30
- Ran Wei · 1 shared paper, 2025 · strength 0.28
- Po‐Chih Yang · 1 shared paper, 2020 · strength 0.13
- Uei Pua · 1 shared paper, 2020 · strength 0.13
- Man Deuk Kim · 1 shared paper, 2020 · strength 0.13
- Po‐Chin Liang · 1 shared paper, 2020 · strength 0.13
- Kai‐Wen Huang · 1 shared paper, 2020 · strength 0.13
- Xiaoyong Li · 1 shared paper, 2020 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.